siRNA targeting Vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects

Virology

Volumn 348, Issue 2, 2006, Pages 489-497

  Dave, Rajnish S ^a   McGettigan, James P ^b   Qureshi, Tazeen ^a   Schnell, Matthias J ^b   Nunnari, Giuseppe ^a   Pomerantz, Roger J ^a  

^a Center for Human Virology   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

E3L; Innate immunity; RNAi; siRNA; Vaccinia

Indexed keywords

BETA INTERFERON; DOUBLE STRANDED RNA BINDING PROTEIN; RNA BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; E3L GENE; EMBRYO; FEMALE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS GENE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; DOWN-REGULATION; GENES, VIRAL; HELA CELLS; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; MODELS, BIOLOGICAL; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC; TRANSFECTION; VACCINIA VIRUS; VARIOLA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

POXVIRIDAE; VACCINIA VIRUS;

EID: 33646235386     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.01.013     Document Type: Article

References (41)

1. Alcami A., and Smith G.L. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69 8 (1995) 4633-4639
2. Alcami A., Symons J.A., Collins P.D., Williams T.J., and Smith G.L. Blockade of chemokine activity by a soluble chemokine binding protein from Vaccinia virus. J. Immunol. 160 2 (1998) 624-633
3. Beattie E., Paoletti E., and Tartaglia J. Distinct patterns of IFN sensitivity observed in cells infected with Vaccinia K3L- and E3L-mutant viruses. Virology 210 2 (1995) 254-263
4. Brandt T.A., and Jacobs B.L. Both carboxy- and amino-terminal domains of the Vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J. Virol. 75 2 (2001) 850-856
5. Brandt T., Heck M.C., Vijaysri S., Jentarra G.M., Cameron J.M., and Jacobs B.L. The N-terminal domain of the Vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology 333 2 (2005) 263-270
6. Bronte V., Carroll M.W., Goletz T.J., Wang M., Overwijk W.W., Marincola F., Rosenberg S.A., Moss B., and Restifo N.P. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. U.S.A. 94 7 (1997) 3183-3188
7. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 5567 (2002) 550-553
8. Carroll K., Elroy-Stein O., Moss B., and Jagus R. Recombinant Vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase. J. Biol. Chem. 268 17 (1993) 12837-12842
9. Chang H.W., Watson J.C., and Jacobs B.L. The E3L gene of Vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 89 11 (1992) 4825-4829
10. Chang H.W., Uribe L.H., and Jacobs B.L. Rescue of Vaccinia virus lacking the E3L gene by mutants of E3L. J. Virol. 69 10 (1995) 6605-6608
11. Colamonici O.R., Domanski P., Sweitzer S.M., Larner A., and Buller R.M. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270 27 (1995) 15974-15978
12. Cullen B.R. RNA interference: antiviral defense and genetic tool. Nat. Immunol. 3 7 (2002) 597-599
13. Dasgupta S., Fernandez L., Kameyama L., Inada T., Nakamura Y., Pappas A., and Court D.L. Genetic uncoupling of the dsRNA-binding and RNA cleavage activities of the Escherichia coli endoribonuclease RNase III-The effect of dsRNA binding on gene expression. Mol. Microbiol. 28 3 (1998) 629-640
14. Dave R.S., and Pomerantz R.J. RNA interference: on the road to an alternate therapeutic strategy!. Rev. Med. Virol. 13 6 (2003) 373-385
15. Dave R.S., and Pomerantz R.J. Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J. Virol. 78 24 (2004) 13687-13696
16. Davies M.V., Chang H.W., Jacobs B.L., and Kaufman R.J. The E3L and K3L Vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67 3 (1993) 1688-1692
17. Denzler K.L., and Jacobs B.L. Site-directed mutagenic analysis of reovirus sigma 3 protein binding to dsRNA. Virology 204 1 (1994) 190-199
18. Diven D.G. Poxviruses. In: Tyring S.K., and Yen-Moore A. (Eds). Mucocutaneous Manifestations of Viral Diseases (2000), Marcel Drekker, New York
19. Earl P.L., and Moss B. In: Ausubel F.M., Kinston R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. (Eds). Current Protocols in Molecular Biology (1991), Greene/Wiley Interscience, New York 16.18.1-16.18.10
20. Esposito J., and Fenner F. Poxviruses. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th ed. vol. 2 (2000), Lippincott-Raven Press, New York NY
21. Garcia M.A., Guerra S., Gil J., Jimenez V., and Esteban M. Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of Vaccinia virus, E3L. Oncogene 21 55 (2002) 8379-8387
22. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., and Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11 3 (2005) 263-270
23. Janeway Jr. C.A., Travers P., Walport M., and Shlomchik M.J. Immunobiology. 5th ed. (2001), Garland Publishing, New York
24. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., and Maclachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23 4 (2005) 457-462
25. Kaufman R.J. Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. Proc. Natl. Acad. Sci. U.S.A. 96 21 (1999) 11693-11695
26. Kaufman R.J. In: Tavantzis S.M. (Ed). dsRNA Genetic Elements: Concepts and Applications in Agriculture, Forestry, and Medicine (2002), CRC Press, New York
27. Kotwal G.J., Isaacs S.N., McKenzie R., Frank M.M., and Moss B. Inhibition of the complement cascade by the major secretory protein of Vaccinia virus. Science 250 4982 (1990) 827-830
28. Langland J.O., and Jacobs B.L. The role of the PKR-inhibitory genes, E3L and K3L, in determining Vaccinia virus host range. Virology 299 1 (2002) 133-141
29. Langland J.O., and Jacobs B.L. Inhibition of PKR by Vaccinia virus: role of the N- and C-terminal domains of E3L. Virology 324 2 (2004) 419-429
30. Li W.X., Li H., Lu R., Li F., Dus M., Atkinson P., Brydon E.W., Johnson K.L., Garcia-Sastre A., Ball L.A., Palese P., and Ding S.W. Interferon antagonist proteins of influenza and Vaccinia viruses are suppressors of RNA silencing. Proc. Natl. Acad. Sci. U.S.A. 101 5 (2004) 1350-1355
31. Lichner Z., Silhavy D., and Burgyan J. Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defenses. J. Gen. Virol. 84 Pt. 4 (2003) 975-980
32. Liu Y., Wolff K.C., Jacobs B.L., and Samuel C.E. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity. Virology 289 2 (2001) 378-387
33. Ludwig H., Mages J., Staib C., Lehmann M.H., Lang R., and Sutter G. Role of viral factor E3L in modified Vaccinia virus Ankara infection of human HeLa cells: regulation of the virus life cycle and identification of differentially expressed host genes. J. Virol. 79 4 (2005) 2584-2596
34. Marcus P.I., and Sekellick M.J. Defective interfering particles with covalently linked [+/-] RNA induce interferon. Nature 266 5605 (1977) 815-819
35. Moss B. Poxviridae: the viruses and their replication. In: Fields B.K., Howley D.M., P.M., et al. (Eds). Virology. Third ed. (1996), Lippincott-Raven, Philadelphia 2637-2671
36. Moss B. Poxviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th ed. vol. 2 (2001), Lippincott-Raven Press, New York NY
37. Sui G., Soohoo C., Affar el B., Gay F., Shi Y., and Forrester W.C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 99 8 (2002) 5515-5520
38. Symons J.A., Alcami A., and Smith G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81 4 (1995) 551-560
39. Whitmore M.M., DeVeer M.J., Edling A., Oates R.K., Simons B., Lindner D., and Williams B.R. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64 16 (2004) 5850-5860
40. Xiang Y., Condit R.C., Vijaysri S., Jacobs B., Williams B.R., and Silverman R.H. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of Vaccinia virus. J. Virol. 76 10 (2002) 5251-5259
41. Yu J.Y., DeRuiter S.L., and Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 99 9 (2002) 6047-6052